{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:08:41Z","timestamp":1784930921670,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Biologicals S.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Globally, &gt;80 million new gonorrhea infections occur annually. Here, we assessed barriers to and influences on participation in a gonorrhea clinical trial and the impact of educational intervention. The survey was fielded in the US in March 2022. Higher enrollment of Black\/African Americans and younger individuals than represented in the US demographic distribution reflected the higher incidence of gonorrhea in these groups. Behavioral characteristics and baseline attitudes toward vaccination were collected. Participants were probed on their knowledge of and likelihood to enroll in general and gonorrhea vaccine trials. Participants hesitant to enroll in a gonorrhea vaccine trial were given nine bullets of basic facts about the disease and asked again to rank their likelihood to enroll. Overall, 450 individuals completed the survey. Fewer participants were willing (quite\/very likely) to join a gonorrhea versus a general vaccine trial (38.2% [172\/450] vs. 57.8% [260\/450]). The likelihood to enroll in any vaccine trial or a gonorrhea vaccine trial was greater with higher self-declared knowledge (Spearman\u2019s \u03c1 = 0.277 [p &lt; 0.001] and 0.316 [p &lt; 0.001], respectively) and baseline openness towards vaccination (p &lt; 0.001 for both). Self-declared awareness of gonorrhea was associated with age (p = 0.001), education (p = 0.031), and ethnicity\/race (p = 0.002), with older, more educated, and Black\/African Americans having higher awareness. Males (p = 0.001) and those with more sexual partners (p &lt; 0.001) were more likely to enroll in a gonorrhea vaccine trial. Educational intervention had a significant (p &lt; 0.001) impact on hesitancy. Improvement in willingness to enroll in a gonorrhea vaccine trial was greatest in those initially marginally hesitant and lowest in those initially strongly hesitant. Basic educational intervention has the potential to improve recruitment into gonorrhea vaccine trials.<\/jats:p>","DOI":"10.3390\/vaccines11030648","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T06:14:58Z","timestamp":1678774498000},"page":"648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Impact of Educational Intervention on Willingness to Enroll in a Clinical Trial of a Gonorrhea Vaccine"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0638-7627","authenticated-orcid":false,"given":"Michael","family":"Penlington","sequence":"first","affiliation":[{"name":"GlaxoSmithKline Biologicals S.A., Avenue Fleming 20, 1300 Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Nicolay","sequence":"additional","affiliation":[{"name":"GSK Vaccines GmbH, Emil-von-Behring-Stra\u00dfe 76, 35041 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Galgani","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline S.p.A., Via Fiorentina 1, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"ref_1","unstructured":"WHO (2023, January 18). Sexually Transmitted Infections Fact Sheet. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis)."},{"key":"ref_2","unstructured":"WHO (2023, January 18). Multi-Drug Resistant Gonorrhoea Fact Sheet. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/multi-drug-resistant-gonorrhoea."},{"key":"ref_3","unstructured":"CDC (2023, January 18). National Overview of Sexually Transmitted Diseases, Available online: https:\/\/www.cdc.gov\/std\/statistics\/2020\/overview.htm#Disparities."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Haese, E.C., Thai, V.C., and Kahler, C.M. (2021). Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea. Vaccines, 9.","DOI":"10.3390\/vaccines9070804"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1473-3099(21)00812-4","article-title":"Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: A retrospective observational study","volume":"22","author":"Abara","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1473-3099(21)00754-4","article-title":"Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: An observational cohort and case-control study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: A retrospective case-control study","volume":"390","author":"Paynter","year":"2017","journal-title":"Lancet"},{"key":"ref_8","unstructured":"McKinsey & Company (2023, January 18). Fast-Forward: Will the Speed of COVID-19 Vaccine Development Reset Industry Norms?. Available online: https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/fast-forward-will-the-speed-of-covid-19-vaccine-development-reset-industry-norms."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_10","unstructured":"ClinicalTrials.gov (2023, January 10). NCT04350138, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04350138."},{"key":"ref_11","unstructured":"ClinicalTrials.gov (2023, January 10). NCT04415424, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04415424."},{"key":"ref_12","unstructured":"CDC (2023, January 18). Reported STDs in the United States Fact Sheet, Available online: https:\/\/www.cdc.gov\/nchhstp\/newsroom\/docs\/factsheets\/STD-Trends-508.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/OLQ.0000000000001332","article-title":"Planning for a gonococcal vaccine: A narrative review of vaccine development and public health implications","volume":"48","author":"Abara","year":"2021","journal-title":"Sex Transm. Dis."},{"key":"ref_14","unstructured":"CDC (2023, January 18). Sexually Transmitted Disease Surveillance Report, Available online: https:\/\/www.cdc.gov\/std\/stats18\/STDSurveillance2018-full-report.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/hiv.12753","article-title":"Association between knowledge, risk behaviours, and testing for sexually transmitted infections among men who have sex with men: Findings from a large online survey in the United Kingdom","volume":"20","author":"Wayal","year":"2019","journal-title":"HIV Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1071\/SH18238","article-title":"Low sexually transmissible infection knowledge, risk perception and concern about infection among men who have sex with men and transgender women at high risk of infection","volume":"16","author":"Dolezal","year":"2019","journal-title":"Sex. Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2037640","DOI":"10.1001\/jamanetworkopen.2020.37640","article-title":"Assessment of the inclusion of racial\/ethnic minority, female, and older individuals in vaccine clinical trials","volume":"4","author":"Flores","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1310\/hct1501-14","article-title":"Minorities remain underrepresented in HIV\/AIDS research despite access to clinical trials","volume":"15","author":"Cohn","year":"2014","journal-title":"HIV Clin. Trials"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41581-022-00571-2","article-title":"COVID-19 vaccine hesitancy","volume":"18","author":"Dube","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"770985","DOI":"10.3389\/fpubh.2021.770985","article-title":"COVID-19 vaccine hesitancy in the United States: A systematic review","volume":"9","author":"Yasmin","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Duong, T.V., Lin, C.Y., Chen, S.C., Huang, Y.K., Okan, O., Dadaczynski, K., and Lai, C.F. (2021). Oxford COVID-19 vaccine hesitancy in school principals: Impacts of gender, well-being, and coronavirus-related health literacy. Vaccines, 9.","DOI":"10.3390\/vaccines9090985"},{"key":"ref_22","unstructured":"Kahn, B., Brown, L., Foege, W., and Gayle, H. (2020). Framework for Equitable Allocation of COVID-19 Vaccine, The National Academies Press."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1016\/j.vaccine.2022.06.015","article-title":"The effect of health literacy on COVID-19 vaccine hesitancy among community population in China: The moderating role of stress","volume":"40","author":"Zhang","year":"2022","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fukuda, Y., Ando, S., and Fukuda, K. (2021). Knowledge and preventive actions toward COVID-19, vaccination intent, and health literacy among educators in Japan: An online survey. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0257552"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1016\/S2468-2667(21)00096-7","article-title":"Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): A single-blind, parallel-group, randomised controlled trial","volume":"6","author":"Freeman","year":"2021","journal-title":"Lancet Public Health"},{"key":"ref_26","unstructured":"US Food and Drug Administration (2022, December 10). Enhancing the Diversity of Clinical Trial Populations\u2014Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/127712\/download."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/picr.PICR_206_19","article-title":"Recruitment and retention of the participants in clinical trials: Challenges and solutions","volume":"11","author":"Chaudhari","year":"2020","journal-title":"Perspect. Clin. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cts.12142","article-title":"Public interest in medical research participation: Differences by volunteer status and study type","volume":"7","author":"Cobb","year":"2014","journal-title":"Clin. Transl. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/2229-3485.184820","article-title":"Challenges in recruitment and retention of clinical trial subjects","volume":"7","author":"Kadam","year":"2016","journal-title":"Perspect. Clin. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1056\/NEJMp2022269","article-title":"COVID-19, ebola, and HIV-Leveraging lessons to maximize impact","volume":"383","author":"Celum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1016\/j.vaccine.2020.09.044","article-title":"The relationship between parental source of information and knowledge about measles\/measles vaccine and vaccine hesitancy","volume":"38","author":"Ashkenazi","year":"2020","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41591-021-01459-7","article-title":"Understanding COVID-19 vaccine hesitancy","volume":"27","author":"Machingaidze","year":"2021","journal-title":"Nat. Med."},{"key":"ref_33","unstructured":"CDC (2023, March 02). Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, Available online: https:\/\/www.cdc.gov\/std\/statistics\/prevalence-2020-at-a-glance.htm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrurol.2017.139","article-title":"Infection: Proof of principle for effectiveness of a gonorrhoea vaccine","volume":"14","author":"Unemo","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.2105\/AJPH.2013.301706","article-title":"A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders","volume":"104","author":"George","year":"2014","journal-title":"Am. J. Public Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-022-31441-x","article-title":"Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021","volume":"13","author":"Lazarus","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41591-021-01454-y","article-title":"COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries","volume":"27","author":"Warren","year":"2021","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gendler, Y., and Ofri, L. (2021). Investigating the influence of vaccine literacy, vaccine perception and vaccine hesitancy on Israeli parents\u2019 acceptance of the COVID-19 vaccine for their children: A cross-sectional study. Vaccines, 9.","DOI":"10.3390\/vaccines9121391"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1080\/21645515.2021.1984123","article-title":"The effect of health literacy on vaccine hesitancy among Italian anticoagulated population during COVID-19 pandemic: The moderating role of health engagement","volume":"17","author":"Magon","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Voo, J.Y.H., Lean, Q.Y., Ming, L.C., Md Hanafiah, N.H., Al-Worafi, Y.M., and Ibrahim, B. (2021). Vaccine knowledge, awareness and hesitancy: A cross sectional survey among parents residing at Sandakan District, Sabah. Vaccines, 9.","DOI":"10.3390\/vaccines9111348"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Khalil, L., Leary, M., Rouphael, N., Ofotokun, I., Rebolledo, P.A., and Wiley, Z. (2022). Racial and ethnic diversity in SARS-CoV-2 vaccine clinical trials conducted in the United States. Vaccines, 10.","DOI":"10.3390\/vaccines10020290"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.puhe.2021.02.025","article-title":"Vaccine hesitancy in the era of COVID-19","volume":"194","author":"Troiano","year":"2021","journal-title":"Public Health"},{"key":"ref_43","unstructured":"U.S. Census Bureau (2023, January 18). QuickFacts: Population Estimates: United States, 1 July 2021 (V2021), Available online: https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045221."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sallam, M. (2021). COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. Vaccines, 9.","DOI":"10.1101\/2020.12.28.20248950"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Svendsen, M.T., Bak, C.K., Sorensen, K., Pelikan, J., Riddersholm, S.J., Skals, R.K., Mortensen, R.N., Maindal, H.T., Boggild, H., and Nielsen, G. (2020). Associations of health literacy with socioeconomic position, health risk behavior, and health status: A large national population-based survey among Danish adults. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-08498-8"},{"key":"ref_46","unstructured":"United States Census Bureau (2023, January 18). Educational Attainment in the United States: 2020, Available online: https:\/\/www.census.gov\/data\/tables\/2020\/demo\/educational-attainment\/cps-detailed-tables.html."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00126334-200405010-00009","article-title":"Determinants of enrollment in a preventive HIV vaccine trial: Hypothetical versus actual willingness and barriers to participation","volume":"36","author":"Buchbinder","year":"2004","journal-title":"Acquir. Immune Defic. Syndr."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:54:33Z","timestamp":1760122473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["vaccines11030648"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11030648","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}